Become a Digital Authority on Keratoconus (Dr. Neda Shamie)

Woman on balcony using phone

Every year, millions of Americans search the web for health-related information, many of whom are looking to learn more about a specific disease or treatment option. By leveraging this natural migration to online research and education, you can grow your practice and become a known resource for the keratoconus community.

A few simple digital marketing strategies you can implement to help reach your goals include:

  • Support patient education
  • Optimize your practice website for keratoconus
  • Establish a social media presence

Dr. Neda Shamie, of Maloney-Shamie Vision Institute, attended Millennial Eye 2019 to share how maintaining a strong digital presence has helped bring millennial keratoconus patients and their families into her practice. While half of the practice’s keratoconus patients are coming from their collaborative network of optometrists, the other half are coming from internet promotion and direct-to-consumer information that is spread online thanks to her digital marketing efforts.

Dr. Neda Shamie

Patient Education

During the interview, Dr. Shamie discussed the importance of educating patients, particularly on the positive progress being made in insurance reimbursement for iLink™ FDA-approved cross-linking. Since finances are often a barrier to receiving treatment, and insurance coverage has changed quickly over the last few years, sharing insurance-related updates has proved to be beneficial to both patients and ODs.

“Education is really important, empowering the patient with the right information so that when the decision to get the treatment comes along they feel empowered with that information.”

Optimizing Your Practice Website for Keratoconus

Since keratoconus typically affects the younger populace, it’s vital to have an online presence and to update your website to include keratoconus content front and center. Dr. Shamie also noted that when ODs see that your website establishes your authority and expertise on the disease, they are more likely to refer patients to your practice.

Social Media Presence

Dr. Shamie maintains a personal Instagram account where she shares a mix of photos and videos that gives her audience a peek into her personal and professional life. She features videos highlighting surgeries, patient interactions, and information on iLink™ FDA-approved cross-linking, but also includes photos of her family to help build a relationship with her audience.

If you’re unsure how to start marketing your keratoconus expertise, start by updating your practice website to include information on keratoconus and iLink™ FDA-approved cross-linking, and establish a social media presence on channels like Facebook and Instagram for the practice and/or doctors.

Click here to watch the full interview.

Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL® System, the iLink™ corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*1

[Photrexa IFU/p1/col1/para3/lines1-4]


Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epethelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, go to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.


1. Photrexa [package insert]. Waltham, MA: Glaukos, Inc. 2016